OverviewChartNewsTraderScreen

BVT Knock-Out GNMSF/  DE000VP16DR3  /

Frankfurt Zert./VONT
30/08/2024  19:53:26 Chg.-0.060 Bid21:59:57 Ask21:59:57 Underlying Strike price Expiration date Option type
3.560EUR -1.66% -
Bid Size: -		 -
Ask Size: -		 Genmab A/S 1,596.96 DKK 31/12/2078 Call
GlobeNewswire 19/08 TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults wit...
GlobeNewswire 16/08 Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and C...
GlobeNewswire 13/08 Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 08/08 Genmab Announces Financial Results for the First Half of 2024
GlobeNewswire 08/08 Genmab Updates 2024 Financial Guidance
GlobeNewswire 05/08 Avalyn Appoints Erin Lavelle, Seasoned Biopharma Finance Executive, to its Board of Directors
GlobeNewswire 05/08 BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update
GlobeNewswire 05/08 Genmab Takes Full Control of Acasunlimab Development Program
GlobeNewswire 30/07 BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patie...
GlobeNewswire 22/07 BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024
GlobeNewswire 28/06 Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Re...
GlobeNewswire 27/06 Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the E...
GlobeNewswire 24/06 BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT...
GlobeNewswire 01/06 Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates M...
GlobeNewswire 29/05 BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
GlobeNewswire 21/05 Genmab Completes Acquisition of ProfoundBio
GlobeNewswire 21/05 BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO A...
GlobeNewswire 17/05 BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
GlobeNewswire 14/05 Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization...
GlobeNewswire 14/05 Immatics Announces First Quarter 2024 Financial Results and Business Update
GlobeNewswire 06/05 BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
GlobeNewswire 02/05 Genmab Announces Financial Results for the First Quarter of 2024
GlobeNewswire 30/04 TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire 22/04 BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
GlobeNewswire 07/04 Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persis...